IOL Chemicals and Pharmaceuticals Toekomstige groei

Future criteriumcontroles 4/6

IOL Chemicals and Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 29.2% en 10.6% per jaar. De winst per aandeel zal naar verwachting groeien met 29.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 10.5% zijn.

Belangrijke informatie

29.2%

Groei van de winst

29.2%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	17.5%
Inkomstengroei	10.6%
Toekomstig rendement op eigen vermogen	10.5%
Dekking van analisten	Low
Laatst bijgewerkt	20 Jan 2025

Recente toekomstige groei-updates

Recent updates

Investors Still Aren't Entirely Convinced By IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Earnings Despite 26% Price Jump

Dec 20

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Somewhat Strained Balance Sheet

Nov 19

A Piece Of The Puzzle Missing From IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Share Price

Sep 11

Is There An Opportunity With IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) 34% Undervaluation?

Jun 12

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

Aug 30

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Pretty Healthy Balance Sheet

May 18

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Will Pay A Dividend Of ₹4.00

Feb 10

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

Jun 07

Calculating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)

May 07

Do IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Warrant Your Attention?

May 04

Is IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) An Attractive Dividend Stock?

Mar 13

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

Feb 23

Should You Rely On IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) Earnings Growth?

Feb 08

IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 27

How Does IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Salary Compare to Peers?

Jan 15

Estimating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)

Jan 02

Shareholders of IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Must Be Delighted With Their 869% Total Return

Dec 21

Is Now The Time To Put IOL Chemicals and Pharmaceuticals (NSE:IOLCP) On Your Watchlist?

Dec 09

These 4 Measures Indicate That IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Is Using Debt Reasonably Well

Nov 24

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Could Be A Buy For Its Upcoming Dividend

Nov 12

Is There More To The Story Than IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Growth?

Nov 09

Will Weakness in IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Stock Prove Temporary Given Strong Fundamentals?

Oct 27

Here's What We Think About IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Pay

Oct 09

Calculating The Fair Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)

Sep 18

Here's Why I Think IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Might Deserve Your Attention Today

Sep 03

Cautious Investors Not Rewarding IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Performance Completely

Aug 16

Winst- en omzetgroeiprognoses

NSEI:IOLCP - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	26,731	2,168	N/A	2,934	1
3/31/2026	24,980	1,911	39	2,280	2
3/31/2025	22,547	1,460	377	1,950	2
9/30/2024	20,524	998	-1,586	1,273	N/A
6/30/2024	20,720	1,185	N/A	N/A	N/A
3/31/2024	21,328	1,344	159	2,901	N/A
12/31/2023	22,161	1,716	N/A	N/A	N/A
9/30/2023	22,192	1,723	62	2,582	N/A
6/30/2023	22,153	1,503	N/A	N/A	N/A
3/31/2023	22,171	1,391	-895	1,223	N/A
12/31/2022	22,024	1,041	N/A	N/A	N/A
9/30/2022	22,341	1,204	-538	824	N/A
6/30/2022	22,305	1,353	N/A	N/A	N/A
3/31/2022	21,840	1,677	-602	931	N/A
12/31/2021	20,719	2,132	N/A	N/A	N/A
9/30/2021	20,298	2,879	703	2,228	N/A
6/30/2021	20,254	3,840	N/A	N/A	N/A
3/31/2021	19,670	4,446	2,716	3,798	N/A
12/31/2020	19,481	4,596	N/A	N/A	N/A
9/30/2020	19,463	4,428	2,902	3,779	N/A
6/30/2020	18,618	4,035	N/A	N/A	N/A
3/31/2020	18,945	3,613	3,905	4,708	N/A
12/31/2019	18,753	3,727	N/A	N/A	N/A
9/30/2019	18,423	3,569	N/A	N/A	N/A
6/30/2019	18,163	3,076	N/A	N/A	N/A
3/31/2019	16,853	2,367	2,126	2,732	N/A
12/31/2018	15,506	1,465	N/A	N/A	N/A
9/30/2018	13,350	731	N/A	N/A	N/A
6/30/2018	11,298	391	N/A	N/A	N/A
3/31/2018	9,833	277	N/A	1,197	N/A
12/31/2017	8,891	178	N/A	N/A	N/A
9/30/2017	8,094	100	N/A	N/A	N/A
6/30/2017	8,265	65	N/A	N/A	N/A
3/31/2017	7,107	47	N/A	833	N/A
12/31/2016	6,595	39	N/A	N/A	N/A
9/30/2016	6,197	-74	N/A	N/A	N/A
6/30/2016	6,055	-214	N/A	N/A	N/A
3/31/2016	5,804	-400	N/A	177	N/A
12/31/2015	5,131	-692	N/A	N/A	N/A
9/30/2015	4,377	-890	N/A	N/A	N/A
6/30/2015	4,008	-858	N/A	N/A	N/A
3/31/2015	3,847	-667	N/A	-470	N/A
12/31/2014	4,405	-378	N/A	N/A	N/A
9/30/2014	5,115	-71	N/A	N/A	N/A
6/30/2014	5,452	37	N/A	N/A	N/A
3/31/2014	5,635	33	N/A	784	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei IOLCP ( 29.2% per jaar) ligt boven de spaarquote ( 6.7% ).

Winst versus markt: De winst van IOLCP ( 29.2% per jaar) zal naar verwachting sneller groeien dan de Indian markt ( 17.8% per jaar).

Hoge groeiwinsten: De winst van IOLCP zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van IOLCP ( 10.6% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.6% per jaar).

Hoge groei-inkomsten: De omzet van IOLCP ( 10.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen IOLCP zal naar verwachting over 3 jaar laag zijn ( 10.5 %).

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/01/23 06:39
Aandelenkoers aan het einde van de dag	2025/01/23 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2024/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

IOL Chemicals and Pharmaceuticals Limited wordt gevolgd door 3 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
null null	Antique Stockbroking Ltd.
Rohit Bhat	Batlivala & Karani Securities India Pvt. Ltd.
Kameswari V. S. Chavali	FirstCall Research

IOL Chemicals and Pharmaceuticals Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 10% to ₹434

Price target decreased by 8.9% to ₹471

Price target increased by 15% to ₹517

Price target increased by 13% to ₹510

Price target increased to ₹575

Price target increased to ₹575

Recent updates

Investors Still Aren't Entirely Convinced By IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Earnings Despite 26% Price Jump

Price target decreased by 10% to ₹434

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Somewhat Strained Balance Sheet

Second quarter 2025 earnings released: EPS: ₹3.26 (vs ₹6.45 in 2Q 2024)

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 14, 2024

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Vikas Vij as Chief Executive Officer, Effective 30 September 2024

A Piece Of The Puzzle Missing From IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Share Price

Investor sentiment improves as stock rises 21%

IOL Chemicals and Pharmaceuticals Limited Announces Resignation of Sandhya Mehta as Independent Director

Full year 2024 earnings: EPS and revenues miss analyst expectations

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 09, 2024

Price target decreased by 8.9% to ₹471

Is There An Opportunity With IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) 34% Undervaluation?

Full year 2024 earnings: EPS and revenues miss analyst expectations

IOL Chemicals and Pharmaceuticals Limited, Annual General Meeting, Aug 23, 2024

IOL Chemicals and Pharmaceuticals Limited to Report Q4, 2024 Results on May 14, 2024

Price target increased by 15% to ₹517

IOL Chemicals and Pharmaceuticals Limited Announces CDE, China Approved Metformin Hydrochloride

IOL Chemicals and Pharmaceuticals Limited Approves Closing of M/S Iol Global Limited, Uk, Wholly Owned Subsidiary of the Company

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 06, 2024

Second quarter 2024 earnings released: EPS: ₹6.45 (vs ₹2.71 in 2Q 2023)

New major risk - Revenue and earnings growth

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 08, 2023

Investor sentiment improves as stock rises 17%

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Pretty Healthy Balance Sheet

Price target increased by 13% to ₹510

IOL Chemicals and Pharmaceuticals Receives Cep for Paracetamol to Export in European Market

Full year 2023 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 19%

Upcoming dividend of ₹4.00 per share at 1.3% yield

IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Will Pay A Dividend Of ₹4.00

Third quarter 2023 earnings released: EPS: ₹4.05 (vs ₹6.82 in 3Q 2022)

IOL Chemicals and Pharmaceuticals Limited Declares Interim Dividend for the Fiscal Year 2023, Payable Before 8 March 2023

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 07, 2023

Investor sentiment improved over the past week

Second quarter 2023 earnings released: EPS: ₹2.71 (vs ₹5.26 in 2Q 2022)

Price target increased to ₹575

IOL Chemicals and Pharmaceuticals Limited Receives EDQM Certification to Supply Pantoprazole Sodium Sesquihydrate API in European Market

IOL Chemicals and Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 14, 2022

Full year 2022 earnings released: EPS: ₹28.56 (vs ₹76.21 in FY 2021)

IOL Chemicals and Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?

Full year 2022 earnings released: EPS: ₹28.56 (vs ₹76.21 in FY 2021)

Now 20% undervalued

IOL Chemicals and Pharmaceuticals Limited Announces Executive Changes

IOL Chemicals and Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Calculating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)

Price target increased to ₹575

IOL Chemicals and Pharmaceuticals Limited Commences the Commercial Production of 'Paracetamol' with Installed Capacity of 1,800 MTPA Along with Backward Integration of Para Amino Phenol (PAP) with Effect from 22 April 2022

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Now 23% undervalued after recent price drop

Upcoming dividend of ₹4.00 per share

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

IOL Chemicals and Pharmaceuticals Limited Declares Interim Dividend for the Financial Year 2021-222, Payable Before 5 March 2022

IOL Chemicals and Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 04, 2022

Upcoming dividend of ₹2.00 per share

President of Project recently sold ₹3.5m worth of stock

First quarter 2022 earnings released: EPS ₹11.41 (vs ₹22.30 in 1Q 2021)

Full year 2021 earnings released: EPS ₹76.21 (vs ₹63.51 in FY 2020)

Do IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Warrant Your Attention?

Joint MD & Whole Time Director has left the company

IOL Chemicals and Pharmaceuticals Limited Appoints Sanjay Chaturvedi as Chief Executive Officer

Is IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) An Attractive Dividend Stock?

Investor sentiment improved over the past week